# Biotech Daily Digest â€” 2026-01-10

**11 items from 2 sources**

## Summary by Source

- Endpoints News: 8 items
- Fierce Biotech: 3 items


## Endpoints News

- **[Eikon Therapeutics files for IPO, testing biotech rally](https://endpoints.news/eikon-therapeutics-files-for-ipo-testing-biotech-rally/)**  
  _Fri, 09 Jan 2026 22:14:35 +0000_  
  Eikon Therapeutics has filed for an IPO, in what would be a bellwether for whether the optimism that has rallied the biotech market can also support IPO prospects for some of ...

- **[How Merck plans to set a buffer for Keytruda's patent cliff](https://endpoints.news/how-merck-plans-to-set-a-buffer-for-keytrudas-patent-cliff/)**  
  _Fri, 09 Jan 2026 20:03:19 +0000_  
  Drip by drip, in hospitals and chemo clinics worldwide, Merckâ€™s Keytruda has been saving patientsâ€™ lives since 2014.

 With each drop into an IV tube, the blockbuster drug recruits the bodyâ€™s natural defenses to fight ...

- **[Aktis' 25% IPO bounce builds hope for 2026's public offerings](https://endpoints.news/aktis-25-ipo-bounce-builds-hope-for-2026s-public-offerings/)**  
  _Fri, 09 Jan 2026 18:44:41 +0000_  
  The first sign of this year's biotech IPO market is a good one.

 On Friday, Aktis Oncology's shares {$AKTS} rose 25% in their debut day of trading, an early signal that after years of dormant ...

- **[Orca adds $250M in financing to back launch of T cell therapy](https://endpoints.news/orca-adds-250-million-in-financing-to-back-launch-of-t-cell-therapy/)**  
  _Fri, 09 Jan 2026 17:08:30 +0000_  
  Orca Bio has pulled together $250 million in new financing for the commercial launch of its treatment for complications from allogeneic stem cell transplants.

 The money comes in part from two of Orcaâ€™s most recent ...

- **[Novartis to build fourth US radiotherapy factory in Florida](https://endpoints.news/novartis-to-build-fourth-us-radiotherapy-factory-in-florida/)**  
  _Fri, 09 Jan 2026 16:36:40 +0000_  
  Novartis is building a new radioligand therapy factory in Florida as part of the companyâ€™s $23 billion US manufacturing pledge.

 The 35,000-square-foot facility in Winter Park, FL will be operational by 2029 and will supply ...

- **[Venture firm a16z raises $700M; Ribo Life's $230M Hong Kong IPO](https://endpoints.news/venture-firm-a16z-raises-700m-ribo-lifes-230m-hong-kong-ipo/)**  
  _Fri, 09 Jan 2026 16:26:48 +0000_  
  Plus, news about Madrigal, Pfizer, Aquestive and Ascendis:
 

 ðŸ’° a16z re-ups its biotech capital pool: The storied VC firm raised $700 million for its Bio + Health strategy, representing a sliver of the ...

- **[BioNTech, UPenn team up for $50M seed fund](https://endpoints.news/biontech-upenn-team-up-for-50m-seed-fund/)**  
  _Fri, 09 Jan 2026 16:25:30 +0000_  
  Two giants and longtime collaborators in the mRNA world are partnering for an early-stage venture fund.

 BioNTech and the University of Pennsylvania are joining up for a $50 million initiative that will invest in startups ...

- **[Krystal Biotech says it can deliver native protein to cystic fibrosis patients](https://endpoints.news/krystal-biotech-says-it-can-deliver-native-protein-to-cystic-fibrosis-patients/)**  
  _Fri, 09 Jan 2026 15:26:44 +0000_  
  Krystal Biotech disclosed promising early findings for a â€˜mutation-agnosticâ€™ treatment for cystic fibrosis, and it wants to head directly into a pivotal trial for the gene therapy.

 Vertex Pharmaceuticals' cystic fibrosis treatments have been game ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/marketing/orca-rides-250m-funding-wave-toward-cancer-cell-therapy-launch" hreflang="en">Orca rides $250M funding wave toward cancer cell therapy launch</a>](https://www.fiercebiotech.com/marketing/orca-rides-250m-funding-wave-toward-cancer-cell-therapy-launch)**  
  _Jan 9, 2026 10:49am_  
  Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the commercialization of a blood cancer cell therapy.

- **[<a href="https://www.fiercebiotech.com/biotech/madrigal-pays-50m-pfizer-mash-drug-could-be-combined-rezdiffra" hreflang="en">Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential</a>](https://www.fiercebiotech.com/biotech/madrigal-pays-50m-pfizer-mash-drug-could-be-combined-rezdiffra)**  
  _Jan 9, 2026 9:08am_  
  Madrigal paid Pfizer $50 million for the rights to a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.

- **[<a href="https://www.fiercebiotech.com/medtech/quanterix-nabs-illuminas-cco-new-leader-leerink-warns-significant-lift-needed-turnaround" hreflang="en">Quanterix nabs Illuminaâ€™s CCO as new leader, but Leerink warns of â€˜significant liftâ€™ needed for turnaround </a>](https://www.fiercebiotech.com/medtech/quanterix-nabs-illuminas-cco-new-leader-leerink-warns-significant-lift-needed-turnaround)**  
  _Jan 9, 2026 8:56am_  
  Quanterix has a new chief executive and president in Everett Cunningham, but analysts at Leerink see Illuminaâ€™s former commercial chief facing an uphill battle in his bid to turn the medtechâ€™s fortunes around.
